MS Matters: Exploring the bi-directional relationship between MS and comorbidities

10/11/2019, 1:30 PM 11.10.2019 13:30 - 11.10.2019 14:30


Prof. Sven Schippling (Moderator):
University Hospital Zürich, Switzerland

Dr Marja-Liisa Sumelahti (Co-presenter):
Tampere University, Finland 

Following the success of the first three CONy & Teva MS Matters live webinars, we are delighted to invite you to attend the fourth in the series – MS Matters: Exploring the bi-directional relationship between MS and comorbidities

Join us for an interactive discussion moderated by Prof. Sven Schippling, during which he and Dr Marja-Liisa Sumelahti will discuss the interplay between MS and its associated comorbidities.

Discussion will focus on evidence on the underlying MS pathology increasing susceptibility to psychiatric and physical comorbidities, while considering the psychological effects of having a degenerative, chronic disease. Comorbidities have been linked with a detrimental impact on diagnosis and disease progression, and may exacerbate MS symptoms, with subsequent reductions in quality of life. The discussion will also carefully consider the requirements for treating patients with MS who have comorbidities; an adapted treatment approach may be required in order to maximise the quality of life of these patients.

Registration details are provided at the bottom of this page.

During the webinar we will discuss

1. The comorbidities associated with MS
2. How the underlying pathology of MS can be cause of psychiatric and physical comorbidities
3. The impact of comorbidities on disease course and quality of life for patients with MS
4. What to consider when treating a patient with MS depending on his/her comorbidity profile



Time (CEST) Title Speaker
13:30 - 13:35 Welcome and introduction Sven Schippling
13:35 - 13:45 An underlying pathology: A two-way street  Marja-Liisa Sumelahti 
13:45 - 13:50  Audience Q&A  All 
13:50 - 14:00  Comorbidities and quality of life in patients with MS  Sven Schippling 
14:00 - 14:05  Audience Q&A  All 
14:05 - 14:20  Considerations for managing MS patients with comorbidities  Marja-Liisa Sumelahti 
14:20 - 14:25  Audience Q&A  All 
14:25 - 14:30 Closing remarks  Sven Schippling


Faculty biographies

Prof. Sven Schippling
University Hospital Zürich, Switzerland

Sven Schippling is currently Deputy Head of the Department of Neuroimmunology and Clinical Multiple Sclerosis Research (nims) at the University Hospital Zürich, Switzerland. He is also the Co-Director of the Clinical Research Priority Program MS (CRPPMS) and Consultant Neurologist at the Department of Neurology at University Hospital Zürich.

Prof. Schippling is a Senior Group Leader at the Neuroscience Centre Zürich of the Federal Technical high school Zürich and the University of Zürich. Prior to this, he was Head of the first MS Day Clinic in Germany at the University Medical Center of Hamburg University, Germany. From 2005 to 2006 he was a postdoctoral research fellow at the Institute of Neurology, University College London, UK and the National Hospital for Neurology and Neurosurgery, London.

Prof. Schippling’s areas of special interest are clinical neuroimmunology mainly within the fields of MS and neuromyelitis optica. His research focuses on multimodal imaging methods in MS, such as magnetic resonance imaging and optical coherence tomography, transcranial magnetic stimulation and clinical trials including stem cell therapies in MS (haematopoietic and mesenchymal). 

Dr Marja-Liisa Sumelahti  
Tampere University, Finland  

Marja-Liisa Sumelahti is currently Associate Professor of Neurology at the Neuroimmunology Unit, Faculty of Medicine and Life Science, University of Tampere, Tampere, Finland.

After graduating in medicine in 1991 at the University of Tampere, Dr Sumelahti became a specialist in Neurology in 1998 and in 2002 completed her PhD titled Occurrence and natural course of multiple sclerosis in Finland. She has since become a specialist in epidemiology, health economics and treatment practice in MS.

Dr Sumelahti has been the principal investigator on several Phase 2 and 3 randomised clinical trials in MS, with much of her research focusing on the interplay between comorbidities and MS. Most recently, she and co-authors published a study investigating common comorbidities in MS and their link to survival (Murtonen A et al. Mult Scler Relat Disord. 2018 Jan;19:109-11).


Go to our webinar page to register for the event

Register here Register here